Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: A comparative pilot study

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Stȩpień, Mariusz ^a   Stȩpień, Anna ^a   Wlazeł, Rafał N ^a   Paradowski, Marek ^a   Banach, Maciej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic inflammation; Hypertension; Obesity; Obesity indices

Indexed keywords

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; WAIST CIRCUMFERENCE;

EID: 84894230780     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-29     Document Type: Article

References (43)

1. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Bastard JP, Maachi M, Lagathu C, et al. Eur Cytokine Net 2006 17 1 4 12
2. The role of the immune system in obesity and insulin resistance. Patel PS, Buras ED, Balasubramanyam A, J Obesity 2013 9 pages ID 616193, dx.doi.org/10.1155/2013/61693
3. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Balistreri CR, Caruso C, Candore G, Mediat Inflamm 2010 19 pages article ID 802078, doi:10.1155/2010/802078
4. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA, Int J Endocrinol 2013 11 pages article ID 678159, dx.doi.org/10.1155/2013/678159
5. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Fuentes E, Fuentes F, Vilahur G, et al. Mediat Inflamm 2013 11 pages article ID 136584, doi:10.1155/2013/136584
6. Adipokines in obesity. de Oliveira Leal V, Mafra D, Clin Chim Acta 2013 419 87 94 23422739
7. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Blüher M, Best Prac Res Clin Endocrinol Metab 2013 27 163 177 10.1016/j.beem.2013.02.005
8. Immune regulation in obesity-associated adipose inflammation. Han JM, Levings MK, J Immunol 2013 191 527 532 10.4049/jimmunol.1301035 23825387
9. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Fain JN, Mediat Inflamm 2010 20 pages ID 513948; doi:10.1155/2010/513948
10. Adipokines in inflammation and metabolic disease. Ouchi N, Parker JL, Lugus JJ, Walsh K, Nat Rev Immunol 2011 11 85 97 10.1038/nri2921 21252989
11. Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Sell H, Eckel J, Curr Opin Clin Nutr Metab Care 2010 13 366 370 10.1097/MCO.0b013e32833aab7f 20473150
12. Chronic and degenerative diseases. Obesity, inflammation and the immune system. 5§ssup§th§esup§ International Immunonutrition Workshop. De Heredia FP, Gmez-Martínez S, Marcos A, Proc Nutr Soc 2012 71 332 338 10.1017/S0029665112000092 22429824
13. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Maury E, Brichard SM, Mol Cell Endocrinol 2010 314 1 16 10.1016/j.mce.2009.07.031 19682539
14. Biochemistry of adipose tissue: an endocrine organ. Coelho M, Oliveira T, Fernandes R, Arch Med Sci 2013 9 191 200 23671428
15. Inflammation, abdominal obesity and smoking as predictors of hypertension. Niskanen L, Laaksonen DE, Nyyssönen K, et al. Hypertension 2004 44 859 865 10.1161/01.HYP.0000146691.51307.84 15492131 (Pubitemid 39577412)
16. Is hypertension an inflammatory process? Boos CJ, Lip GYH, Curr Pharm Design 2006 12 1623 1635 10.2174/138161206776843313
17. Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions. Dagenais NJ, Jamali F, Pharmacother 2005 25 1213 1229 10.1592/phco.2005.25.9.1213 (Pubitemid 41244813)
18. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients-pilot study. Stȩpień M, Wlazeł RN, Paradowski M, et al. Arch. Med. Sci. 2012 8 431 436 22851996
19. Predictors of insulin resistance in patients with obesity: a pilot study. Stepien M, Stepien A, Wlazel RN, et al. Angiology 2014 65 1 22 30 10.1177/0003319712468291 23267236
20. Indices of abdominal obesity are better discrimination of cardiovascular risk factor than BMI: a meta-analysis. Lee CM, Huxley RR, Widma RP, Woodward M, J Clin Epidem 2008 61 646 653 10.1016/j.jclinepi.2007.08.012
21. Visceral Adiposity Index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Amato MC, Giordano C, Galia M, for the AlkaMeSy Study Group, et al. Diabetes Care 2010 33 920 922 10.2337/dc09-1825 20067971
22. A better index of body adiposity. Bergman RN, Stefanovski D, Buchanan TA, et al. Obesity 2011 19 1083 1089 10.1038/oby.2011.38 21372804
23. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Lapice E, Maione S, Patti L, et al. Diabetes Care 2009 32 1734 1736 10.2337/dc09-0176 19587368
24. Comparison of different anthropometric measurements and inflammatory biomarkers. Arbel Y, Birati EY, Shapira I, et al. Int J Inflam 2012 2012 124693 doi:10.1155/2012/124693 22675656
25. New indices of visceral adiposity and its correlation with hs-CRP in patients with obesity. Stȩpień A, Stȩpień M, Wlazeł RN, et al. Clin Exp Med Lett 2011 52 91 95
26. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Pannacciulli N, Cajntatore FP, Menenna A, et al. Int J Obes 2001 25 1416 1420 10.1038/sj.ijo.0801719 (Pubitemid 32977856)
27. Body adiposity index versus body mass index and anthropometric traits as correlates of cardiometabolic risk factors. Lichtash CT, Cui J, Guo X, et al. PloS ONE 2013 8 6 65954 10.1371/journal.pone.0065954 23776578
28. Associations between body mass index and serum levels of C-reactive protein. Thung-Wei K, Lu IS, Kuo-Chen L, et al. S Afr Med J 2009 99 326 330 19588793
29. Association between adiponectin and mediators of inflammation in obese women. Engeli S, Feldpausch M, Gorzelniak K, et al. Diabetes 2003 52 942 947 10.2337/diabetes.52.4.942 12663465 (Pubitemid 36384264)
30. New obesity indices and adipokines in normotensive patients and patients with hypertension. Stepien M, Stepien A, Banach M, et al. Angiology 2013 doi:10.1177/000331971348580
31. Sex differences in human adipose tissues-the biology of pear shape. Karastergiou K, Smith SR, Greenberg AS, Fried SK, Biol Sex Differ 2012 3 13 10.1186/2042-6410-3-13 22651247
32. Sex dimorphism and depot differences in adipose tissue function. White UA, Tchoukalova YD, Biochim Biophys Acta 2014 1842 3 377 92 dx.doi.org/10.1016/ j.bbadis.2013.05.006 10.1016/j.bbadis.2013.05.006 23684841
33. Relationship of obesity and visceral obesity with serum concentrations of CRP, TNF- and IL-6. Park HS, Park JY, Yu R, Diab Res Clin Pract 2005 69 29 35 10.1016/j.diabres.2004.11.007 (Pubitemid 40813409)
34. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Saijo Y, Kiyota N, Kawasaki Y, et al. Diabetes, Obesity and Metabolism 2004 6 249 258 10.1111/j.1462-8902.2003.0342.x (Pubitemid 38807798)
35. The inflammatory markers: C-Reactive Protein and TNF- predict cardiovascular risk in obese North Indian subjects. Khan R, Haque SF, Quaiser S, Biomed Res 2011 22 475 480
36. Correlation of circulating inflammatory markers, ghrelin, adiponectin with obesity indices in subjects with metabolic syndrome. Gharipour M, Sadeghi M, Mansourian M, et al. Pak J Med Sci 2013 29 264 268
37. Correlations of tumor necrosis factor- and interleukin-6 with anthropometric indices of obesity and parameters of insulin resistance in healthy north Indian population. Agraval N, Chitrika A, Bhattacharjee J, Jain SK, JIACM 2011 12 196 204
38. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. Belfort R, Berria R, Cornell J, Cusi K, J Clin Endocrinol Metab 2010 95 829 836 10.1210/jc.2009-1487 20061429
39. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Chan DC, Watts GF, Barrett HR, et al. Clin Chem 2002 48 877 883 12029003 (Pubitemid 34587587)
40. Statin reduces C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. Park OY, Kim SH, Ahn YK, et al. Chonnam Med J 2008 44 13 16 10.4068/cmj.2008.44.1.13
41. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects-a meta-analysis of randomized controlled trials. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, Narkiewicz K, Rysz J, Ray KK, Abdollahi M, Int J Cardiol 2013 168 3 2816 2824 10.1016/j.ijcard.2013.03.068 23602289
42. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Stȩpień M, Stȩpień A, Wlazeł RN, Paradowski M, Banach M, Rysz M, Rysz J, Med Sci Monit 2013 19 1063 1072 24280776
43. Lipids, blood pressure, kidney-what was new in 2011? Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M, Arch Med Sci 2011 7 6 1055 1066 22328891